Smith & Nephew
About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Employees: 18,000
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
6% more capital invested
Capital invested by funds: $900M [Q2] → $952M (+$52.6M) [Q3]
0% more funds holding
Funds holding: 206 [Q2] → 206 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 30
0.65% less ownership
Funds ownership: 4.16% [Q2] → 3.5% (-0.65%) [Q3]
8% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 76
67% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 1 (-2) [Q3]
86% less call options, than puts
Call options by funds: $28K | Put options by funds: $206K
Research analyst outlook
We haven’t received any recent analyst ratings for SNN.
Financial journalist opinion
Based on 5 articles about SNN published over the past 30 days
Positive
Zacks Investment Research
4 days ago
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA
Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.
Neutral
GlobeNewsWire
5 days ago
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome.
Positive
Zacks Investment Research
1 week ago
SNN Stock Might Rise Following FDA Nod for AETOS Stemless
Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.
Neutral
GlobeNewsWire
1 week ago
Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless).
Positive
Proactive Investors
3 weeks ago
Smith & Nephew has the potential to pop next year, says leading US investment bank
JP Morgan has doubled down on its "overweight" recommendation for Smith & Nephew PLC (LSE:SN) with its analysts deeming the medical device company undervalued, trading near trough levels, with potential for significant re-rating. Despite challenges in the broader European medtech sector, S&N stands out as a value pick with promising recovery prospects.
Negative
Reuters
1 month ago
Big investors call for break-up of Smith & Nephew, FT reports
Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.
Positive
Seeking Alpha
1 month ago
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine.
Neutral
Seeking Alpha
1 month ago
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.
Negative
Proactive Investors
1 month ago
Smith+Nephew slashes revenue outlook as China headwinds emerge
British medical equipment manufacturer Smith & Nephew PLC (LSE:SN) slashed its full-year revenue outlook to account for a downturn in demand and pricing pressures in the Chinese market. The FTSE 100-listed group now expects full-year revenue growth of 4.5%, compared to 5-6% growth previously expected.
Negative
Reuters
1 month ago
Smith & Nephew slashes annual revenue forecast on weak China
British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.
Charts implemented using Lightweight Charts™